Part 1: Currently Accepted Glaucoma Practice <br>1. Pathophysiology <br>2. Epidemiology <br>3. Diagnosis and investigations <br>4. Follow-up <br>5. Treatments <br>6. Section Summary: Discussion on the major unmet needs of the specialty<br><br>Part 2: Pathophysiology and investigation methods <br>7. Glaucoma epidemiology: the role of genetics and biomarkers <br>8. Considerations for an efficient screening programmes for glaucoma <br>9. Ocular perfusion in glaucoma and the role of arterial blood pressure <br>10. The role of circadian and extrinsic intraocular pressure fluctuations<br>11. Pseudo-exfoliative glaucoma: epidemiology, pathophysiology and their clinical impact<br>12. Retinal and optic nerve micro-perfusion and the role of OCT-A<br>13. Structural testing modalities: cicrumpapillary RNFL, BMO-MRW, macular RNFL or vessel density?<br>14. Statistical considerations on visual field testing: how frequent is frequent-enough?<br>15. Novelties in functional testing: the role of contrast sensitivity, electrophysiology and colour vision<br>16. Section Summary: Diagnosing the grey zone and follow-up considerations<br><br>Part 3: Medical and laser therapies<br>17. Social and psychological aspects of treatment adherence<br>18. Topical medications and ocular surface<br>19. Novel pressure-lowering medications and research alternatives<br>20. Novel drug delivery methods<br>21. Matrix metalloproteinase<br>22. Medical lasers, basic principles and core differences<br>23. Physiological principles and effects of SLT; discussion over the LIGHT Trial<br>24. Prophylactic iridotomy in narrow angle glaucoma<br>25. Aqueous dynamics, glaucoma and corneal health (considerations for iridotomies) <br>26. Section Summary: Recommendations in treatment-naïve open-angle glaucoma, treatment escalation protocols, and patient-specific considerations <br><br>Part 4: Surgical options<br>27. Anatomical, mechanical and physiological effect of cataract surgery in open and narrow angle glaucoma<br>28. Anatomical considerations on trabecular meshwork, Schlemm’s canal and collecting channels<br>29. The role of ocular inflammation, fluid dynamics and bleb morphology in surgical outcomes (including long-term conjunctival sensitization with fibroblast, aqueous inflammatory markers, and effect of aqueous flow on bleb viability; and considerations on early/delayed surgery)<br>30. Aqueous angiography and targeted surgery<br>31. Minimally-invasive glaucoma surgery (MIGS) device design considerations<br>32. Novel approaches to aqueous drainage<br>33. Adjustable drainage devices: benefits and shortcomings<br>34. Implantable intraocular pressure sensors and telemedicine<br>35. Laser-assisted surgery<br>36. Considerations on glaucoma clinical trials <br>37. Section Summary: Surgical considerations: Finding the best patient-surgeon-procedure match<br><br>Part 5: New technologies <br>38. Artificial intelligence and Big Data: technical considerations and clinical applications<br>39. Detection of apoptosing retinal cells (DARC) in glaucoma<br>40. Neuroprotection and neurostimulation<br>41. Clinical trials in neuroprotection: special considerations<br>42. Neuro-regeneration and stem-cell therapies<br>43. Gene therapy<br>44. Section Summary: Predicting the future of glaucoma practice
